JP4313435B2 - プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 - Google Patents
プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 Download PDFInfo
- Publication number
- JP4313435B2 JP4313435B2 JP50696497A JP50696497A JP4313435B2 JP 4313435 B2 JP4313435 B2 JP 4313435B2 JP 50696497 A JP50696497 A JP 50696497A JP 50696497 A JP50696497 A JP 50696497A JP 4313435 B2 JP4313435 B2 JP 4313435B2
- Authority
- JP
- Japan
- Prior art keywords
- nmda
- response
- sulfate
- estradiol
- 5β3αs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title claims description 100
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title claims description 31
- DIJBBUIOWGGQOP-QGVNFLHTSA-N pregnenolone sulfate Chemical class C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 DIJBBUIOWGGQOP-QGVNFLHTSA-N 0.000 title description 189
- 230000000694 effects Effects 0.000 title description 83
- 230000005764 inhibitory process Effects 0.000 title description 38
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 18
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 16
- 230000030833 cell death Effects 0.000 claims description 16
- 230000001684 chronic effect Effects 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 13
- 201000006474 Brain Ischemia Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 206010015037 epilepsy Diseases 0.000 claims description 9
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 208000006011 Stroke Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 239000001961 anticonvulsive agent Substances 0.000 claims description 6
- 206010013663 drug dependence Diseases 0.000 claims description 6
- 229960005309 estradiol Drugs 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 5
- 230000000147 hypnotic effect Effects 0.000 claims description 5
- 239000003158 myorelaxant agent Substances 0.000 claims description 5
- 208000004296 neuralgia Diseases 0.000 claims description 5
- 239000000932 sedative agent Substances 0.000 claims description 5
- 210000004958 brain cell Anatomy 0.000 claims description 4
- 239000003326 hypnotic agent Substances 0.000 claims description 4
- 230000016273 neuron death Effects 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 229940125723 sedative agent Drugs 0.000 claims description 4
- YHVRYYYYYRDIAL-UHFFFAOYSA-N n,n-dimethyl-2-(4-nitrophenoxy)ethanamine Chemical compound CN(C)CCOC1=CC=C([N+]([O-])=O)C=C1 YHVRYYYYYRDIAL-UHFFFAOYSA-N 0.000 claims description 3
- 239000004090 neuroprotective agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 196
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 195
- 230000004044 response Effects 0.000 description 130
- 150000003431 steroids Chemical class 0.000 description 73
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 69
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 58
- 210000002569 neuron Anatomy 0.000 description 40
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 36
- 230000001404 mediated effect Effects 0.000 description 35
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 32
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 31
- 239000004471 Glycine Substances 0.000 description 29
- 230000001105 regulatory effect Effects 0.000 description 28
- 239000000243 solution Substances 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 229930195712 glutamate Natural products 0.000 description 23
- 241000700159 Rattus Species 0.000 description 22
- 238000000034 method Methods 0.000 description 20
- 229940114079 arachidonic acid Drugs 0.000 description 19
- 235000021342 arachidonic acid Nutrition 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 230000001629 suppression Effects 0.000 description 19
- 230000003834 intracellular effect Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 230000001419 dependent effect Effects 0.000 description 17
- 230000002964 excitative effect Effects 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 16
- 229940063675 spermine Drugs 0.000 description 16
- 230000000946 synaptic effect Effects 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 210000000287 oocyte Anatomy 0.000 description 13
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 12
- AURFZBICLPNKBZ-YZRLXODZSA-N 3alpha-hydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-YZRLXODZSA-N 0.000 description 12
- 206010010904 Convulsion Diseases 0.000 description 12
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 11
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 229930195714 L-glutamate Natural products 0.000 description 9
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000036461 convulsion Effects 0.000 description 9
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 9
- MENQCIVHHONJLU-YZRLXODZSA-N 3alpha-Hydroxy-5beta-pregnane-20-one sulfate Chemical compound C([C@H]1CC2)[C@H](OS(O)(=O)=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 MENQCIVHHONJLU-YZRLXODZSA-N 0.000 description 8
- 102000018899 Glutamate Receptors Human genes 0.000 description 8
- 108010027915 Glutamate Receptors Proteins 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 229950007402 eltanolone Drugs 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 210000003657 middle cerebral artery Anatomy 0.000 description 8
- 230000036963 noncompetitive effect Effects 0.000 description 8
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 8
- 229960000249 pregnenolone Drugs 0.000 description 8
- YJPIDPAGJSWWBE-FNIAAEIWSA-N 4-{[(14β,17α)-3-hydroxyestra-1,3,5(10)-trien-17-yl]oxy}-4-oxobutanoic acid Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OC(=O)CCC(O)=O)[C@@H]4[C@@H]3CCC2=C1 YJPIDPAGJSWWBE-FNIAAEIWSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 7
- 108090000862 Ion Channels Proteins 0.000 description 7
- 102000004310 Ion Channels Human genes 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 7
- 230000007831 electrophysiology Effects 0.000 description 7
- 238000002001 electrophysiology Methods 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229920000768 polyamine Polymers 0.000 description 7
- 230000004224 protection Effects 0.000 description 7
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 210000001168 carotid artery common Anatomy 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000001054 cortical effect Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- -1 for example Chemical class 0.000 description 6
- 230000000971 hippocampal effect Effects 0.000 description 6
- 210000004295 hippocampal neuron Anatomy 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- ZMITXKRGXGRMKS-UHFFFAOYSA-N Androsteronsulfat-pyridiniumsalz Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 ZMITXKRGXGRMKS-UHFFFAOYSA-N 0.000 description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 5
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- ZMITXKRGXGRMKS-HLUDHZFRSA-N androsterone sulfate Chemical compound C1[C@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 ZMITXKRGXGRMKS-HLUDHZFRSA-N 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 5
- 229950009829 prasterone sulfate Drugs 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 230000001242 postsynaptic effect Effects 0.000 description 4
- 238000009738 saturating Methods 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- RWVIMCIPOAXUDG-UHFFFAOYSA-N 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C([N+]([O-])=O)=C2 RWVIMCIPOAXUDG-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 150000008051 alkyl sulfates Chemical class 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000003837 chick embryo Anatomy 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 230000002461 excitatory amino acid Effects 0.000 description 3
- 239000003257 excitatory amino acid Substances 0.000 description 3
- 230000003492 excitotoxic effect Effects 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- DXVBUJOATHQUCY-UHFFFAOYSA-N hydroxy-methyl-sulfanyl-sulfanylidene-$l^{5}-phosphane Chemical group CP(O)(S)=S DXVBUJOATHQUCY-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000007775 late Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229940035363 muscle relaxants Drugs 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000012402 patch clamp technique Methods 0.000 description 3
- 229950010883 phencyclidine Drugs 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 150000005845 steroid sulfates Chemical class 0.000 description 3
- 230000002739 subcortical effect Effects 0.000 description 3
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical group NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 238000011870 unpaired t-test Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 2
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 206010043994 Tonic convulsion Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- AURFZBICLPNKBZ-SYBPFIFISA-N brexanolone Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-SYBPFIFISA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 2
- 229950004794 dizocilpine Drugs 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 210000000609 ganglia Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000003961 neuronal insult Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000004963 pathophysiological condition Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000004224 potassium gluconate Substances 0.000 description 2
- 235000013926 potassium gluconate Nutrition 0.000 description 2
- 229960003189 potassium gluconate Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000176 sodium gluconate Substances 0.000 description 2
- 235000012207 sodium gluconate Nutrition 0.000 description 2
- 229940005574 sodium gluconate Drugs 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 230000009154 spontaneous behavior Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000009782 synaptic response Effects 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- LNSMPSPTFDIWRQ-GSVOUGTGSA-N (2r)-4-amino-2-(methylamino)-4-oxobutanoic acid Chemical compound CN[C@@H](C(O)=O)CC(N)=O LNSMPSPTFDIWRQ-GSVOUGTGSA-N 0.000 description 1
- GINNQWJVZGSMNA-VCDGUJLRSA-N (8R,9S,13S,14S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound C(=O)(O)C1(CC[C@@H]2[C@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3)O GINNQWJVZGSMNA-VCDGUJLRSA-N 0.000 description 1
- ULAADVBNYHGIBP-GFEQUFNTSA-N (8r,9s,13s,14s,17s)-3-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-ol Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 ULAADVBNYHGIBP-GFEQUFNTSA-N 0.000 description 1
- ORNBQBCIOKFOEO-QYYVTAPASA-N 1-[(3r,8s,9s,10r,13s,14s,17s)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C1C=C2C[C@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QYYVTAPASA-N 0.000 description 1
- IQGZWLYDESGLID-WKHXEXGJSA-N 1-[(3s,8s,9s,10r,13s,14s,17s)-3-hydroxy-6,10,13-trimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]ethanone Chemical compound C1C(C)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 IQGZWLYDESGLID-WKHXEXGJSA-N 0.000 description 1
- LNOBZXNCABUBKK-UHFFFAOYSA-N 2,3,5-triphenyltetrazolium Chemical compound C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LNOBZXNCABUBKK-UHFFFAOYSA-N 0.000 description 1
- KUAHVIUZGLGASU-UHFFFAOYSA-N 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid;hydrobromide Chemical compound Br.CC=1ON=C(O)C=1CC(N)C(O)=O KUAHVIUZGLGASU-UHFFFAOYSA-N 0.000 description 1
- QWUGXTUSOZVHEM-UHFFFAOYSA-N 20-deoxypregnenolone Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(CC)C1(C)CC2 QWUGXTUSOZVHEM-UHFFFAOYSA-N 0.000 description 1
- MOIQRAOBRXUWGN-WPWXJNKXSA-N 21-hydroxypregnenolone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC=C21 MOIQRAOBRXUWGN-WPWXJNKXSA-N 0.000 description 1
- HREDZMAPXFYEQW-LTFPLMDUSA-N 3-Hydroxy-19-norpregna-1,3,5(10)-trien-20-one Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 HREDZMAPXFYEQW-LTFPLMDUSA-N 0.000 description 1
- MGMOLZNAUACBCR-UHFFFAOYSA-N 3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-17-carboxylic acid Chemical compound C1C(O)CCC2(C)C3CCC(C)(C(CC4)C(O)=O)C4C3CC=C21 MGMOLZNAUACBCR-UHFFFAOYSA-N 0.000 description 1
- AURFZBICLPNKBZ-GRWISUQFSA-N 3beta-hydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-GRWISUQFSA-N 0.000 description 1
- UAWVRVFHMOSAPU-UHFFFAOYSA-N 7-chlorokynurenic acid Chemical compound C1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 UAWVRVFHMOSAPU-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 102000000079 Kainic Acid Receptors Human genes 0.000 description 1
- 108010069902 Kainic Acid Receptors Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 108010084867 N-methyl D-aspartate receptor subtype 2A Proteins 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 108010054235 NMDA receptor A1 Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010063843 Phencyclidine Receptors Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 108010015519 Steroid sulfotransferase Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- MENQCIVHHONJLU-ACWDEBGSSA-N [(3s,5r,10s,13s)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C([C@H]1CC2)[C@@H](OS(O)(=O)=O)CC[C@]1(C)C1C2C2CCC(C(=O)C)[C@@]2(C)CC1 MENQCIVHHONJLU-ACWDEBGSSA-N 0.000 description 1
- KRBMZSYRIJAAMS-KIYFCUGLSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 KRBMZSYRIJAAMS-KIYFCUGLSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003906 autonomic nervous system functioning Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 239000003372 dissociative anesthetic agent Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- HJKVPZJVBHWFCQ-BDXSIMOUSA-N estra-1,3,5(10)-trien-3-ol Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 HJKVPZJVBHWFCQ-BDXSIMOUSA-N 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-N methyl hydrogen carbonate Chemical compound COC(O)=O CXHHBNMLPJOKQD-UHFFFAOYSA-N 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 239000003706 n methyl dextro aspartic acid receptor stimulating agent Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940126027 positive allosteric modulator Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 150000003131 pregnenolone derivatives Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- TYRGSDXYMNTMML-UHFFFAOYSA-N propyl hydrogen sulfate Chemical compound CCCOS(O)(=O)=O TYRGSDXYMNTMML-UHFFFAOYSA-N 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 239000002265 redox agent Substances 0.000 description 1
- 230000006697 redox regulation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AFVPZQPJVCUVBY-AQSOIRLBSA-M sodium;4-[[(3r,5r,10s,13s,17s)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoate Chemical compound [Na+].C([C@H]1CC2)[C@H](OC(=O)CCC([O-])=O)CC[C@]1(C)C1C2C2CC[C@H](C(=O)C)[C@@]2(C)CC1 AFVPZQPJVCUVBY-AQSOIRLBSA-M 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 230000008925 spontaneous activity Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US143995P | 1995-07-24 | 1995-07-24 | |
| US60/001,439 | 1995-07-24 | ||
| US50775795A | 1995-07-26 | 1995-07-26 | |
| US08/507,757 | 1995-07-26 | ||
| US08/559,442 | 1995-11-15 | ||
| US08/559,442 US5888996A (en) | 1995-07-26 | 1995-11-15 | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| PCT/US1996/012198 WO1997003677A1 (en) | 1995-07-24 | 1996-07-24 | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH11509844A JPH11509844A (ja) | 1999-08-31 |
| JPH11509844A5 JPH11509844A5 (enExample) | 2009-05-07 |
| JP4313435B2 true JP4313435B2 (ja) | 2009-08-12 |
Family
ID=27356924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50696497A Expired - Fee Related JP4313435B2 (ja) | 1995-07-24 | 1996-07-24 | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6083941A (enExample) |
| EP (1) | EP0840612A1 (enExample) |
| JP (1) | JP4313435B2 (enExample) |
| WO (1) | WO1997003677A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010051599A1 (en) * | 1997-05-02 | 2001-12-13 | Michael Z. Kagan | Pregnan-3-ol-20-ones |
| ES2288028T3 (es) * | 1998-11-10 | 2007-12-16 | Curamentis Ltd. | Uso de agonistas de los receptores de glucocorticosteroides y/o mineralocorticosteroides, especialmente corticosteroides para el tratamiento de la drogadiccion. |
| FR2786102B1 (fr) * | 1998-11-20 | 2001-02-16 | Monique Vincens | Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere |
| GB9917822D0 (en) * | 1999-07-29 | 1999-09-29 | Imperial College | Nmda antagonist |
| US6623933B1 (en) | 1999-08-31 | 2003-09-23 | Trustees Of Boston University | Methods for identifying a subunit specific modulator of N-methyl-D-asparate receptor |
| US20040204490A1 (en) * | 1999-08-31 | 2004-10-14 | Farb David H. | Effect of steroids on NMDA receptors depends on subunit composition |
| GB0003524D0 (en) * | 2000-02-15 | 2000-04-05 | Btg Int Ltd | Cytoprotective steroids (II) |
| GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| WO2002036128A1 (en) * | 2000-11-06 | 2002-05-10 | Trustees Of Boston University | Neuroactive steroid derivatives and methods of use |
| US20030013692A1 (en) * | 2001-01-19 | 2003-01-16 | Gullans Steven R. | Methods of treating neurological disorders |
| JP2005506292A (ja) * | 2001-03-08 | 2005-03-03 | エモリー ユニバーシティ | ｐＨに依存するＮＭＤＡレセプターアンタゴニスト |
| DK1243262T3 (da) * | 2001-03-20 | 2006-10-02 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter |
| ATE228358T1 (de) * | 2001-03-21 | 2002-12-15 | Sanol Arznei Schwarz Gmbh | Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen |
| US7790404B2 (en) * | 2001-08-20 | 2010-09-07 | Sanford-Burnham Medical Research Institute | Excitatory glycine receptors and methods |
| AUPR731901A0 (en) * | 2001-08-28 | 2001-09-20 | Goodchild, Colin Stanley | Method of treatment |
| FR2850023B1 (fr) * | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| IL154318A (en) | 2003-02-06 | 2010-05-31 | Sarah Herzog Memorial Hospital | Pharmaceutical compositions for the treatment of movement disorders |
| DE602004030103D1 (de) * | 2003-04-18 | 2010-12-30 | Advanced Medicine Res Inst | Mittel zur behanldung von krankheiten zur aufbringung auf das auge |
| AU2004294714B2 (en) * | 2003-12-02 | 2009-12-10 | Ucb Pharma Gmbh | Novel use of peptide compounds for treating central neuropathic pain |
| MXPA06007852A (es) * | 2004-01-15 | 2007-01-31 | Warner Chilcott Co Inc | Profarmacos di-esteroidales de estradiol. |
| CN1906207A (zh) * | 2004-01-15 | 2007-01-31 | 沃纳奇尔科特公司 | 乙炔雌二醇的二－甾族前体药物 |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| JP2007532607A (ja) | 2004-04-16 | 2007-11-15 | シュバルツ ファルマ アクチェンゲゼルシャフト | 慢性頭痛の予防及び治療のためのペプチド化合物の使用 |
| EP1604656A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| EP1604655A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| ATE471717T1 (de) * | 2004-08-27 | 2010-07-15 | Ucb Pharma Gmbh | Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen |
| US20060252749A1 (en) * | 2005-01-28 | 2006-11-09 | Srz Properties, Inc. | Lacosamide for add-on therapy of psychosis |
| US7795241B2 (en) * | 2005-07-12 | 2010-09-14 | Warner Chilcott Company, Llc | Derivative prodrugs of ethinyl estradiol |
| WO2007008474A2 (en) * | 2005-07-12 | 2007-01-18 | Warner Chilcott Company, Inc. | 3 -ester prodrugs of estradiol |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| JP4382735B2 (ja) * | 2005-10-06 | 2009-12-16 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
| RU2430737C2 (ru) * | 2005-10-28 | 2011-10-10 | Сон-Ю КИМ | Экстракт семейства диоскорейных (dioscoreaceae) и содержащая его композиция для профилактики или лечения периферической невропатии |
| EP2037965B1 (en) | 2006-06-15 | 2017-08-30 | UCB Pharma GmbH | Pharmaceutical composition with synergistic anticonvulsant effect |
| CN101466390B (zh) * | 2006-06-15 | 2014-03-12 | 优时比制药有限公司 | 用于治疗难治性癫痫持续状态的肽类化合物 |
| US20090203658A1 (en) * | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| EP2170334B1 (en) | 2007-06-29 | 2021-03-17 | Emory University | Nmda receptor antagonists for neuroprotection |
| CA2783331A1 (en) * | 2008-12-09 | 2010-07-08 | King Faisal Specialist Hospital & Research Center | Pregnenolone sulfate for the treatment of neurologic disorders |
| JP6205362B2 (ja) * | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| DK2806877T3 (da) | 2012-01-23 | 2019-11-04 | Sage Therapeutics Inc | Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin |
| FR2992645B1 (fr) * | 2012-07-02 | 2014-08-01 | Univ Claude Bernard Lyon | Nouveaux derives de pyrrolidine |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| JP2016501876A (ja) | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| CZ2014575A3 (cs) * | 2014-08-26 | 2016-02-24 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | Amfifilní sloučeniny s neuroprotektivními účinky |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| PL3436022T3 (pl) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) * | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| EP3988096A1 (en) * | 2020-10-26 | 2022-04-27 | Universidad Pablo de Olavide OTRI | Sulfated c19 steroid hormones to treat and/or prevent proteotoxicity in protein-aggregation diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212167A (en) * | 1991-09-12 | 1993-05-18 | Trustees Of Boston University | Modulation of receptor-mediated ion transport |
| CA2118938A1 (en) * | 1991-09-13 | 1993-04-01 | Kelvin W. Gee | Novel gabaa receptor with steroid binding sites |
| DE69435286D1 (de) * | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
-
1996
- 1996-07-24 WO PCT/US1996/012198 patent/WO1997003677A1/en not_active Ceased
- 1996-07-24 EP EP96926768A patent/EP0840612A1/en not_active Withdrawn
- 1996-07-24 JP JP50696497A patent/JP4313435B2/ja not_active Expired - Fee Related
-
1998
- 1998-01-23 US US09/012,910 patent/US6083941A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6083941A (en) | 2000-07-04 |
| EP0840612A1 (en) | 1998-05-13 |
| JPH11509844A (ja) | 1999-08-31 |
| WO1997003677A1 (en) | 1997-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4313435B2 (ja) | プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制 | |
| JPH11509844A5 (enExample) | ||
| US5888996A (en) | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity | |
| CN104257657B (zh) | 用于治疗cmt和相关疾病的治疗方法 | |
| ES2796250T3 (es) | Composiciones para mejorar la viabilidad celular y los métodos de uso de las mismas | |
| KR102149321B1 (ko) | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 | |
| JP2021507944A (ja) | 運動ニューロン疾患を含む神経障害のための組成物および治療方法 | |
| EP3038614A1 (en) | Composition comprising torasemide and baclofen for treating neurological disorders | |
| EA032881B1 (ru) | Применение торасемида для лечения болезни альцгеймера или родственного болезни альцгеймера расстройства или травмы спинного мозга | |
| US20150025063A1 (en) | Antiparkinsonian Action of Phenylisopropylamines | |
| JP2012515754A (ja) | 神経栄養因子介在疾患の治療 | |
| JP2018076332A (ja) | （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法 | |
| AU2006229840B2 (en) | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | |
| US20160206603A1 (en) | Composition comprising torasemide and baclofen for treating neurological disorders | |
| EA029157B1 (ru) | Терапия макулярной дегенерации на основе баклофена и акампросата | |
| ZA200605791B (en) | Pharmaceutical composition of a sodium channel blocker and a selective serotonin uptake inhibitor | |
| CN106456571B (zh) | 用于治疗机械性神经元损伤的组合物 | |
| WO2024103012A1 (en) | Polycyclic compounds for use in neurodegenerative conditions | |
| WO2003015614A2 (en) | Use of clc3 chloride channel blockers to modulate vascular tone | |
| US20110136769A1 (en) | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | |
| CN116139140A (zh) | 一种化合物在治疗糖皮质激素不良反应中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20070125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070213 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070509 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070625 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070813 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080401 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080312 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080529 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090226 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090310 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090424 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090515 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120522 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |